Clinical trials: Epidermis
EGFR Positive Non-small Cell Lung Cancer
Retreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor in EGFR Mutation Positive Patients
In this trial, treatment efficacy and safety of retreatment with 1st generation epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor(TKI)s(Gefitinib/Erlotinib), will be assessed in patients with sensitizing EGFR…
- Trial name
- NCT03382795
- Testing
- EGFR
- Where
- 8 sites in South Korea
- Volunteers
- 63 people
- Sponsor
- Korea University Guro Hospital
Burns
Phase III Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Adults and Adolescents
This multicentre phase III clinical trial will target adults and adolescents of 12 years and older with severe burns to confirm the efficacy and functionality of denovoSkin™ in achieving wound closure and reducing scarring in…
- Trial name
- NCT06745557
- Testing
- denovoSkin(TM), STSG
- Where
- 19 sites in Belgium, France and 7 more
- Volunteers
- 70 people
- Sponsor
- CUTISS AG
Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Real-life Treatment Patterns With Cyclin-dependent Kinase Inhibitors in Advanced Breast Cancer in Portugal - REVEAL Study
This was a non-interventional (observational), retrospective, cohort study of women with hormone receptor (HR)-positive and human epidermal growth factor receptor-type 2 (HER2)-negative advanced breast cancer who started…
- Trial name
- NCT06463626
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Novartis
Recurrent Breast Cancer
A Study of Foretinib in Patients With Recurrent/Metastatic Breast Cancer
The purpose of this study is to find out what effects this new drug foretinib has on this type of breast cancer, called "triple negative" breast cancer because the cancer tissue is estrogen, progesterone and HER2 receptor…
- Trial name
- IND197 (NCT01147484)
- Testing
- Foretinib
- Where
- 9 sites in Canada
- Volunteers
- 47 people
- Sponsor
- NCIC Clinical Trials Group
Preventive Care
Evaluation of the Sub Epidermal Moisture a Device for the Screening of Pressure Ulcer (RELIASEM)
The device that is the subject of this investigation is a diagnostic tool to detect the among of fluid in hypodermis to help to prevent the formation of pressure injuries.
- Trial name
- RELIASEM (NCT04955106)
- Testing
- SEM Scanner
- Where
- France
- Volunteers
- 52 people
- Sponsor
- Arjo France
Non Small Cell Lung Cancer, Brain Metastases
A Study to Determine the Efficiency For Brain Metastasis NSCLC Patients Treated With Icotinib Alone or Combined With Radiation Therapy
The purpose of this study is to evaluate the efficacy of icotinib alone or in combination with radiation therapy for NSCLC patients harboring EGFR mutation with brain metastases. The primary endpoint is overall survival .
- Trial name
- SMART (NCT04058704)
- Testing
- Icotinib, SRS/WBRT/HA-WBRT/SMART
- Where
- China
- Volunteers
- 296 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Breast Cancer
A Study of Subcutaneously Administered Herceptin (Trastuzumab) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer
This open-label, randomized crossover study evaluated the quality of life, efficacy, and safety of subcutaneous Herceptin (trastuzumab) injected either into the thigh or the upper arm of participants with early HER2-positive…
- Trial name
- LISAH (NCT01928615)
- Testing
- Trastuzumab - intravenous solution, Trastuzumab - subcutaneous solution, Chemotherapy
- Where
- 2 sites in Austria
- Volunteers
- 2 people
- Sponsor
- Hoffmann-La Roche
Epidermal Growth Factor Receptor, Non-Small Cell Lung Cancer
Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer
Patient with Non-Small Cell Lung Cancer (NSCLC) that might have a genetic change (mutation) in the Epidermal Growth Factor Receptor (EGFR) are invited to take part in this study.
- Trial name
- NCT02770014
- Testing
- Erlotinib
- Where
- 3 sites in United States
- Volunteers
- 43 people
- Sponsor
- Dana-Farber Cancer Institute
Carcinoma, Non-Small-Cell Lung
Evaluation of the Impact of Nurse-led Telephone on Treatment Compliance
The study will take place over a period of 27 months. The recruitment phase will last approximately 24 months and each patient will participate for approximately 3 months.
- Trial name
- NCT02483416
- Where
- 36 sites in France
- Volunteers
- 30 people
- Sponsor
- Boehringer Ingelheim
Breast Cancer
Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer
The purpose of this study is to find out what effect taking cisplatin in combination with bevacizumab before surgery and then standard chemotherapy plus bevacizumab after surgery will have on participants with Estrogen Receptor…
- Trial name
- NCT00580333
- Testing
- cisplatin, bevacizumab, doxorubicin
- Where
- 3 sites in United States
- Volunteers
- 51 people
- Sponsor
- Massachusetts General Hospital
Healthy
Intra-epidermal Stimulation (IES) of Small Nerve Fibers (A-delta Fibers)
The purpose of the study is to determine whether a particular type of nerve fibers, A-delta fibers, can be tested in an Electromyography (EMG) lab on a routine basis. Normal, healthy volunteers will be enrolled in this study.
- Trial name
- IES (NCT02312752)
- Testing
- Intra-epidermal stimulation electrode
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Minnesota
Head and Neck Cancer, Pelvic Cancer
Health Oriented Protocol for Epidermal Radiodermatitis
Radiation therapy is a standard treatment for malignant tumors of the head and neck and pelvic regions, used alone or in combination with chemotherapy.
- Conditions
- Head and Neck Cancer, Pelvic Cancer, Radiation Skin Injury, Gynecologic Cancer
- Trial name
- HOPE (NCT07129525)
- Testing
- Radiation therapy
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Breast Cancer
NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline
Despite modern surgical and medical treatments, breast cancer can re-occur and lead 20% of patients to death. During the last 20 years, pre-clinical studies have shown that treatment failures may be due to the presence of a…
- Trial name
- NCT06452394
- Testing
- Doxycyclin
- Where
- 8 sites in Switzerland
- Volunteers
- 50 people
- Sponsor
- Swiss Cancer Institute
Breast Neoplasms
A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer
The primary purpose of this study is to evaluate the tolerability and safety of E7090 as monotherapy and in combination with other anticancer agents in participants with ER+, HER2- recurrent/metastatic breast cancer and to…
- Trial name
- NCT04572295
- Testing
- E7090, Fulvestrant, Exemestane
- Where
- 11 sites in Japan
- Volunteers
- 51 people
- Sponsor
- Eisai Co., Ltd.
Non-small Cell Lung Cancer, NSCLC
Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients
This phase 2 study is designed to evaluate the safety and activity of TH-4000 a hypoxia-activated prodrug, in patients with EGFR-Mutant, T790M-Negative, Advanced NSCLC.
- Conditions
- Non-small Cell Lung Cancer, NSCLC, Non-squamous NSCLC
- Trial name
- TH-4000 (NCT02454842)
- Testing
- TH-4000 (Tarloxotinib)
- Where
- 12 sites in United States, Australia
- Volunteers
- 21 people
- Sponsor
- Rain Oncology Inc
Non-Small Cell Lung Cancer
An epidemiOlogy Study to deteRmine the Prevalence of EGFR (Epidermal Growth Factor Receptor) muTations in RUSsian Patients With Advanced NSCLC (Non-Small Cell Lung Cancer).
This is a multicentre, non-interventional, prospective study to be carried out in representative oncology departments / institutions in order to determine the prevalence of EGFR mutations in treatment-naive Russian patients with…
- Trial name
- ORTUS (NCT02321046)
- Where
- 26 sites in Russia
- Volunteers
- 26 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung
Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations
This trial was to explore whether intravenous vitamin C can prolong resistance time of Tyrosine Kinase Inhibitor(TKI) on lung adenocarcinoma patients with Epidermal Growth Factor Receptor(EGFR) mutations, and can benefit NSCLC…
- Trial name
- NCT03799094
- Testing
- Vitamin C, Tyrosine kinase inhibitor
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Clifford Hospital, Guangzhou, China
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
A Study of Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic G/ GEJ Adenocarcinoma
Phase Ib/II clinical study of AK129 combined with chemotherapy with or without cadonilimab in first-line treatment of advanced HER2 negative gastric cancer or gastroesophageal junction adenocarcinoma
- Trial name
- NCT06586294
- Testing
- Drug: AK129 Drug：oxaliplatin Drug：capecitabine, Drug: AK129 Drug: cadonilimab Drug: oxaliplatin Drug: capecitabine
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Akeso
Influenza in Human
Comparison of Laser Assisted Epidermal to Intradermal Administration of Seasonal Influenza Vaccine
It is the aim of the present study to compare the immunogenicity induced by a laser-assisted epidermally administered seasonal influenza vaccine to an intradermally administered seasonal influenza vaccine.
- Trial name
- NCT02988739
- Testing
- seasonal influenza vaccine, fractional Er:Yag laser
- Where
- Austria
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pantec Biosolutions AG
Breast Cancer
Impact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for Women With HR+/HER2- Early Breast Cancer
This single-arm study is designed to test the hypothesis that a six-month intermittent fasting (IF) intervention is feasible for patients to adhere to and improves health-related quality of life while subjects are on adjuvant…
- Trial name
- NCT06106477
- Testing
- Intermittent Fasting
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Medical College of Wisconsin
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.